Citadel Advisors’s LAVA Therapeutics LVTX Stock Holding History

Citadel Advisors’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,800	Closed	-$23.5K	–	13545
2025 Q2	$23.5K	Sell	17,800 -32,300	-64%	-$41.1K	﹤0.01%	12067
2025 Q1	$63.6K	Buy	+50,100	New	+$55.8K	﹤0.01%	12038
2024 Q4	–	Sell	-6,900	Closed	-$11.5K	–	15025
2024 Q3	$11.5K	Sell	6,900 -5,700	-45%	-$10.4K	﹤0.01%	13159
2024 Q2	$22.7K	Buy	12,600 +2,400	+24%	+$6.34K	﹤0.01%	12524
2024 Q1	$34K	Buy	+10,200	New	+$22.4K	﹤0.01%	12569

Citadel Advisors's LVTX Position: Q4 2025 in Review

Citadel Advisors sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 53,308 shares — an estimated $83.2K sold.

Citadel Advisors first reported a position in LVTX in Q1 2021 and held it in 9 quarters. The position peaked at $918K in Q1 2021. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

Citadel Advisors reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 53,308 LAVA Therapeutics shares in Q4 2025, an estimated $83.2K.
Citadel Advisors first reported a position in LAVA Therapeutics in Q1 2021 and held it in 9 quarters.
Citadel Advisors's LAVA Therapeutics position peaked at $918K in Q1 2021.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.